CoChat

Inhibition of PU.1 ameliorates metabolic dysfunction and non-alcoholic steatohepatitis

Liu, Qiongming, Yu, Junjie, Wang, Liheng, Tang, Yuliang, Zhou, Quan, Ji, Shuhui, Wang, Yi, Santos, Luis, Haeusler, Rebecca A., Que, Jianwen, Rajbhandari, Prashant, Lei, Xiaoguang, Valenti, Luca, Pajvani, Utpal B., Qin, Jun, Qiang, Li · 2020 · Journal of Hepatology
Cited by 51

The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.

Abstract

BACKGROUND & AIMS Obesity is a well-established risk factor for type 2 diabetes (T2D) and nonalcoholic steatohepatitis (NASH), but the underlying mechanisms remain incompletely understood. Here, we aimed to identify novel pathogenic factor and therapeutic target of liver metabolic dysfunctions. METHODS We applied tandem quantitative proteomics strategy to enrich and identify transcription factors (TFs) induced in the obese liver. We used flow cytometry of liver cells to analyze the source of the induced TF. We employed conditional knockout mice, shRNA, and small-molecule inhibitors to test metabolic consequences of the induction of identified TF. Finally, we validated mouse data in patient liver biopsies. RESULTS We identified PU.1/SPI1, the master hematopoietic regulator, as one of the most up-regulated TFs in livers from diet-induced (DIO) and genetically obese (db/db) mice. Targeting PU.1 in the whole liver-but not hepatocytes alone-significantly improved glucose homeostasis and suppressed liver inflammation. Consistently, treatment with the PU.1 inhibitor DB1976 markedly reduced inflammation and improved glucose homeostasis and dyslipidemia in DIO mice, and strongly suppressed glucose intolerance, liver steatosis, inflammation, and fibrosis in a dietary NASH mouse model. Furthermore, hepatic PU.1 expression was positively correlated with insulin resistance and inflammation in liver biopsies from patients. CONCLUSIONS These data suggest that the elevated hematopoietic factor PU.1 promotes liver metabolic dysfunctions, and may be a useful therapeutic target for obesity, insulin resistance/T2D, and NASH.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jhep.2020.02.025

Cites

22 of 22 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 22 references

Cited by

See all 51

Metadata

Authors
Liu, Q., Yu, J., Wang, L., Tang, Y., Zhou, Q., Ji, S., Wang, Y., Santos, L., Haeusler, R. A., Que, J., Rajbhandari, P., Lei, X., Valenti, L., Pajvani, U. B., Qin, J., & Qiang, L.
Venue
Journal of Hepatology
Publisher
Elsevier BV
Published
2020-08
Volume
73
Issue
2
Pages
361-370
ISSN
0168-8278 (ISSN-L)
OpenAlex
W3009189519
Cited by
51
References
22
FWCI
3.84
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Inhibition of PU.1 ameliorates metabolic dysfunction and non-alcoholic steatohepatitis. https://app.cochat.ai/papers/10.1016/j.jhep.2020.02.025
The paper
Liu, Q., Yu, J., Wang, L., Tang, Y., Zhou, Q., Ji, S., Wang, Y., Santos, L., Haeusler, R. A., Que, J., Rajbhandari, P., Lei, X., Valenti, L., Pajvani, U. B., Qin, J., & Qiang, L. (2020). Inhibition of PU.1 ameliorates metabolic dysfunction and non-alcoholic steatohepatitis. Journal of Hepatology. https://doi.org/10.1016/j.jhep.2020.02.025

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.